Tuesday, March 19, 2019

Neovascular AMD: Bevacizumab Injection Increases Angiogenic Biomarkers

Dr. Thiago Cabral
Neovascular age-related macular degeneration (nAMD) is induced by the development of new abnormal ‘leaky’ blood vessels in the choroid and retina, when the balance of pro- and anti-angiogenic factors is upset. Vascular endothelial growth factor (VEGF) is considered a critical modulator of angiogenesis and is related to induction of endothelial cell migration and proliferation after hypoxia. The development of anti-VEGF agents, such as bevacizumab (Avastin®), ranibizumab (Lucentis®) and aflibercept (Eylea®), revolutionized the treatment of nAMD.